Cantor Fitzgerald has reaffirmed its Overweight rating on Immunovant (NASDAQ: IMVT) shares, citing the biopharmaceutical company’s 191% gain over the past year and no material changes in its business outlook following its first-quarter earnings report.
The firm’s rating implies an expected outperformance relative to its coverage universe over the next 12 to 18 months. Immunovant’s stock was trading near its 52-week high of $45.42 at the time of the update.
Cantor Fitzgerald also adjusted its financial model for Immunovant’s operating expenses based on the quarterly results, though it noted that no other key metrics had shifted materially. The reiteration comes despite an InvestingPro analysis suggesting the stock may be overvalued relative to its Fair Value estimate at current levels.
The rating follows Immunovant’s first-quarter earnings release, which did not introduce new catalysts affecting the firm’s outlook. Immunovant, a clinical-stage company, remains focused on advancing its pipeline, though its valuation remains a point of debate among analysts.
Separately, Roivant Sciences reported a first-quarter 2026 loss per share of $0.75, missing the expected $0.60 loss by 25%. The company attributed the wider-than-anticipated shortfall to elevated research and development spending ahead of an active second half of the year.
